<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Promoting NAD+ Metabolism: A new Target for Treating Degenerative Disease

Loading...
Thumbnail Image
Unable to use the file because of accessibility barriers? Send us feedback

Publication Date

2016-12-01

Avondale Authors

Publisher

DOI

Rights

Due to copyright restrictions this article is unavailable for download.

Staff and Students of Avondale College may access this article via a Library Primo search here.

Version

Published Version

Review Status

Peer Reviewed

Field of Education

Field of Research

Degree

Department

Faculty

Supervisor

Awarding Institution

Degree

Department

Faculty

Supervisor

Awarding Institution

Abstract

NAD+ is found in every cell of the body and is essential for life. It serves as a cofactor for dehydrogenase, reductase and hydroxylase enzymes where it facilitates electron transfer in major metabolic pathways such as glycolysis, the triacarboxylic acid (TCA) cycle, fatty acid synthesis and steroid hormone synthesis, enabling the conversion of the food we eat into the energy and chemical products the body needs. More recently it has been found that NAD+ is also required as a substrate by enzymes that regulate the expression of genes involved in cell viability and aging and in repair of damaged DNA. Through these reactions, NAD+ influences a variety of cell processes involved in cell health, including improving mitochondrial efficiency, enhancing cell viability, down-regulating inflammation, increasing the antioxidant capacity of cells and tissues, and activating the ‘longevity’ enzyme SIRT1. An increasing body of evidence indicates that enhancing NAD+ availability in the brain has the potential to moderate elements of the neurodegenerative disease processes associated with oxidative stress and aging, including Alzheimer’s disease. However there are difficulties associated with raising NAD+ levels using the classical pathway and vitamin B3 precursors nicotinic acid and nicotinamide. The recent discovery of two alternative naturally occurring B3 vitamins; nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) may resolve these problems. NR in particular has shown good efficacy in its ability to raise NAD+ levels under a variety of conditions. Directly boosting [NAD+] may present a new and exciting approach to preventing the natural decline in cellular energy and function as we age, particularly in the brain.

Description

Research Statement

Citation

Grant, R., Berg, J., & Braidy, N. (2016). Promoting NAD+ metabolism: A new target for treating degenerative disease. Journal of the Australasian College of Nutritional and Environmental Medicine, 35(3), 3-10. Retrieved from https://search.informit.org/doi/10.3316/INFORMIT.584663816365396

Source Title

Journal of the Australasian College of Nutritional and Environmental Medicine

Series

International Standard Serial Number

1328-8040

International Standard Book Number

Avondale University acknowledges our Sovereign God as Creator and Provider of all things. We respectfully acknowledge the Awabakal and Darramuragal people as the traditional custodians of the lands on which we live, work, study and worship across our Lake Macquarie and Sydney campuses. We pay our respects to Elders past, present and emerging, and extend that respect to all First Nations People.

Aboriginal Peoples are advised the Library Collection contains images, voices and names of deceased people in physical and online resources. The Library recognises the significance of the traditional cultural knowledges contained within its Collection. The Library acknowledge some materials contain language that may not reflect current attitudes, was published without consent or recognition, or, is offensive. These materials reflect the views of the authors and/or the period in which they were produced and do not represent the views of the Library.

Avondale University is a member of the worldwide Seventh-day Adventist system of universities and colleges.

CRICOS Provider No.: 02731D. RTO: 91191. TEQSA: PRV12015. ABN: 53 108 186 401.

© Avondale University Ltd 2026